Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas
- PMID: 16875495
- PMCID: PMC2517375
- DOI: 10.1111/j.1365-2613.2006.00482.x
Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas
Abstract
Tumorigenesis involves alterations in the tumor suppressor genes (p53), protooncogenes (BCL-2), and housekeeping genes (human MutS homologue-2 (hMSH2). We hypothesized that development of gliomas is associated with alterations of p53, BCL-2, and hMSH2 protein expression. To test our hypothesis and to examine these issues, we immunostained 60 specimens entailing normal brain tissues, gliosis, and gliomas (Grade I, II, III, IV) for p53, BCL-2, and hMSH2 protein expression. As compared with the normal brain and gliosis, examination of the average weighted scores in gliomas (Grade I, II, III, IV, respectively) showed significant up-regulation of: (i) p53 protein (0.0 +/- 0.0; 0.0 +/- 0.0; 0.9 +/- 0.5; 1.6 +/- 0.8; 1.7 +/- 0.5; and 4.1 +/- 0.8, P < 0.0001) (ii) hMSH2 (1.3 +/- 0.3; 1.5 +/- 0.7; 1.9 +/- 1.1; 2.2 +/- 0.5; 4.1 +/- 1.5; and 4.7 +/- 1.1, P < 0.0006), and (iii) BCL-2 (0.8 +/- 0.5; 1.9 +/- 0.5; 1.9 +/- 0.6; 2.0 +/- 0.6; 4.4 +/- 1.2; and 4.6 +/- 0.8, P < 0.001). The expression values (p53, BCL-2, and hMSH2) were statistically significantly higher (P < 0.05) in astrocytomas (Grade III) than in other gliomas. There was an insignificant negative correlation between p53 and BCL-2 (r = -0.07, P > 0.05) and between p53 and hMSH2 (r = -0.08, P > 0.05) protein expression. Alterations of the p53, BCL-2, and hMSH2 proteins occur during the development of these tumors.
Figures





Similar articles
-
Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the upper Egypt.Cancer Biol Ther. 2004 Oct;3(10):983-8. doi: 10.4161/cbt.3.10.1136. Epub 2004 Oct 2. Cancer Biol Ther. 2004. PMID: 15467428
-
Human gliomas with wild-type p53 express bcl-2.Cancer Res. 1995 Mar 1;55(5):999-1001. Cancer Res. 1995. PMID: 7867012
-
Immunocytochemical detection of p53 in human gliomas.Mod Pathol. 1991 Sep;4(5):671-4. Mod Pathol. 1991. PMID: 1758878
-
The challenge of p53 as prognostic and predictive factor in gliomas.Cancer Treat Rev. 2000 Feb;26(1):67-73. doi: 10.1053/ctrv.1999.0145. Cancer Treat Rev. 2000. PMID: 10660492
-
[The EGF receptor pathway in human cerebral tumors].Neurochirurgie. 1992;38(5):257-66. Neurochirurgie. 1992. PMID: 1299771 Review. French.
Cited by
-
MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway.Cancer Sci. 2014 Mar;105(3):265-71. doi: 10.1111/cas.12351. Epub 2014 Feb 11. Cancer Sci. 2014. Retraction in: Cancer Sci. 2024 Sep;115(9):3200. doi: 10.1111/cas.16269. PMID: 24418124 Free PMC article. Retracted.
-
Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study.Open Dent J. 2015 Jan 30;9:41-5. doi: 10.2174/1874210601509010041. eCollection 2015. Open Dent J. 2015. PMID: 25674170 Free PMC article.
-
Predictive Role of p53 Protein as a Single Marker or Associated to Ki67 Antigen in Oral Carcinogenesis.Open Dent J. 2008;2:24-9. doi: 10.2174/1874210600802010024. Epub 2008 Feb 21. Open Dent J. 2008. PMID: 19088879 Free PMC article.
-
Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways.J Biol Chem. 2012 Jun 1;287(23):19242-54. doi: 10.1074/jbc.M112.349936. Epub 2012 Apr 9. J Biol Chem. 2012. PMID: 22493490 Free PMC article.
-
Integrated analysis of mismatch repair system in malignant astrocytomas.PLoS One. 2013 Sep 20;8(9):e76401. doi: 10.1371/journal.pone.0076401. eCollection 2013. PLoS One. 2013. PMID: 24073290 Free PMC article.
References
-
- Alderson LM, Castleberg RL, Harsh GR., IV Human gliomas with wild-type p53 express bcl-2. Cancer Res. 1995;55:999–1001. - PubMed
-
- Bruner JM, Saya H, Moser RP. Immunocytochemical detection of p53 in human gliomas. Mod Pathol. 1991;4:671–674. - PubMed
-
- Dietzmann K, von Bossanyi P, Sallaba J, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation. Gen Diagn Pathol. 1996;141:339–344. - PubMed
-
- von Eckardstein K, Gries H, Bolik E, et al. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry. Histol. Histopathol. 1997;12:611–616. - PubMed
-
- Fels C, Schafer C, Huppe B, et al. Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. J. Neurooncol. 2000;48:207–216. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous